Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 16;7(4):e1414119. doi: 10.1080/2162402X.2017.1414119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — RT + L19-IL2 triggers long-lasting immunological memory. (A) Tumour-free survival of mice that rejected tumours after 10Gy + L19-IL2 and were re-injected at day 150 with C51 tumour cells, together with a group of naïve mice. (B) Percentage of CD44⁺CD127⁺ cells of splenic CD8⁺ T cells. (C) Confirmation of CD127 inhibition by FACS in peripheral blood at day 3 after CD127 blocking. (D) Tumour-free survival of mice that were cured after different treatments and were re-challenged at day 150 with C51 tumour cells, together with a group of control mice initially injected with matrigel only. (E) Percentages of CD44⁺CD127⁺, CD44⁺CD62L⁺ and CD44⁺CD62L⁻ of total CD8⁺ T cells in blood and lymph nodes. Green symbols represent responders (no tumour take after re-injection) and black symbols represent non-responders. Bars represent median. (F) Representative plots and median percentages of different immune subsets analyzed by FACS in blood, spleens and lymph nodes.